# Kristian Reich

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kristian-reich/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,296 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 105 |
| i10-index | 395 |
| OpenAlex ID | https://openalex.org/A5000572878 |
| ORCID iD | https://orcid.org/0000-0001-5248-4332 |
| Works | 738 |

## Researcher papers

Showing 12 of 19.

- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody-2/)
- [Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/phase-3-trials-of-ixekizumab-in-moderate-to-severe-plaque-psoriasis/)
- [European S3‐Guidelines on the systemic treatment of psoriasis vulgaris](https://scholariq.org/papers/european-s3-guidelines-on-the-systemic-treatment-of-psoriasis-vulgaris/)
- [Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials](https://scholariq.org/papers/tildrakizumab-versus-placebo-or-etanercept-for-chronic-plaque-psoriasis/)
- [Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey](https://scholariq.org/papers/patient-perspectives-in-the-management-of-psoriasis-results-from-the-population/)
- [Epidemiology and comorbidity of psoriasis in children](https://scholariq.org/papers/epidemiology-and-comorbidity-of-psoriasis-in-children/)
- [Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t](https://scholariq.org/papers/dupilumab-with-concomitant-topical-corticosteroid-treatment-in-adults-with/)
- [Bimekizumab versus Secukinumab in Plaque Psoriasis](https://scholariq.org/papers/bimekizumab-versus-secukinumab-in-plaque-psoriasis/)
- [Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up](https://scholariq.org/papers/long-term-safety-of-ustekinumab-in-patients-with-moderate-to-severe-psoriasis/)
- [Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/safety-and-efficacy-of-upadacitinib-in-combination-with-topical-corticosteroids/)
- [Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis](https://scholariq.org/papers/epidemiology-and-clinical-pattern-of-psoriatic-arthritis-in-germany-a/)
- [Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-and-inadequate/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Pharmaceutical studies and practices](https://scholariq.org/topics/pharmaceutical-studies-and-practices/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.